静脉血栓塞栓症预防对患有骨科创伤的患者的处方模式:临床图片调查
Nathan N O'Hara1, Deborah M Stein1, Elliott R Haut2
1University of Maryland School of Medicine, Baltimore, Maryland, USA.
Trauma surgery & acute care open
|September 19, 2024
概括
临床医生仍然主要使用埃诺沙巴林用于骨科创伤后在医院内静脉血栓塞栓症 (VTE) 预防. 然而,阿司匹林越来越多地被认为是出院的药物,特别是当患者缺乏额外的VTE风险因素时.
科学领域:
- 整形外科手术 整形外科手术
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 最近的试验表明,阿司匹林可以替代埃诺沙巴林,用于骨科创伤患者的VTE预防.
- 这些发现对当前处方实践的影响尚不清楚.
研究的目的:
- 评估在治疗骨科创伤患者的临床医生中声明的VTE预防处方模式.
- 评估新的临床证据如何影响VTE预防选择.
主要方法:
- 在40个州的外科医生和高级实践提供者进行了一项临床图片调查.
- 临床医生回顾了详细介绍骨科创伤情景的七个细节,并指示处方VTE预防 (住院和出院).
- 分析了影响处方偏好和实践变化的因素.
主要成果:
- 在83%的住院情景中,埃诺沙林被处方,而阿司匹林在13%的情况中被使用.
- 在出院时,阿司匹林的偏好显著增加 (50%vs. 41%为埃诺沙巴林).
- 如果患者有额外的VTE风险因素,如肥胖,提供者更有可能开处方埃诺沙.
结论:
- 尽管有新的证据,但在医院内VTE预防的做法仍然没有改变.
- 与历史数据相比,临床医生在出院时对阿司匹林的偏好显著增加.
- 额外的血栓塞栓风险因素的存在会影响出院时阿司匹林和埃诺沙巴林之间的选择.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
649
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
649
Disorders of Hemostasis
739
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
739
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
496
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
496


